|
Quantitative Biophotonics for Tissue Characterization and Function
|
Research Initiative
|
FDA
|
OD/OIR, NICHD
|
Quantitative Biophotonics for Tissue Characterization and Function
|
|
Quantum Barcoding for analysis of Ebola infection
|
Other
|
FDA
|
NIAID
|
Viral MIBI and Quantum barcoding: These projects are part of a Food and Drug Administration (FDA) contract with Dr. Gary Nolan's group at Stanford. The first project will develop and validate an assay for nucleic acid-based method for viral detection on the MIBI, compatible with Formalin-Fixed Paraffin-Embedded tissue, and then apply to Ebola samples. The second will use quantum barcoding to develop anti-human and anti-macaque antibody reagents, to hep develop a system that will replace multiplexing technologies such as high parameter FACS and CyTOF with a platform based on sequence tags (rather than fluorophores or mass tags) that uses decontaminated and ambient temperature-stable samples. This will be applied to BSL-3/4 samples.
|
|
Racial and Ethnic Disparities in Excess Deaths During the COVID-19 Pandemic
|
Research Initiative
|
CDC
|
NCI, NIMHD
|
Although racial/ethnic disparities in U.S. COVID-19 death rates are striking, focusing on COVID-19 deaths alone may underestimate the true effect of the pandemic on disparities. Excess death estimates capture deaths both directly and indirectly caused by COVID-19 excess deaths and excess deaths per 100,000 persons from March to December 2020 were estimated by race/ethnicity, sex, age group, and cause of death, using provisional death certificate data from the Centers for Disease Control and Prevention (CDC) and U.S. Census Bureau population estimates.
|
|
Racial/Ethnic Variation of HPV Type Distribution in High-Grade Cervical Precancers and Invasive Cancers in the United States
|
Research Initiative
|
CDC
|
NCI
|
The National Cancer Institute (NCI) and Centers for Disease Control and Prevention (CDC) are collaborating in pooled analysis of seven U.S. studies conducted between 1997-2015 to examine HPV genotype attribution for cervical precancer and cancer by race/ethnicity.
|
|
Radiation and Chemical Defense Working Group
|
Committee, Work group, Advisory group, or Task Force
|
ASPR, FDA
|
NIAID, NIEHS, NIAMS
|
This group is responsible for ensuring that any scientific or budgetary overlap between the chemical defense and radiation defense missions are identified and leveraged to advance the missions of both research areas. Goals are to understand areas of synergy in chemical and radiological insults, identify key pathways, foci of intervention, MCM development. The group includes staff from across the NIH, FDA and ASPR. Special Journal Issue and Government staff positional paper are planned.
|
|
Radiation Biodosimetry Working Group
|
Committee, Work group, Advisory group, or Task Force
|
FDA
|
NIAID
|
This working group is focused on regulatory and scientific issues regarding technologies and devices for radiation biodosimetry. The working group assisted in drafting the new Food and Drug Administration (FDA) Center for Device and Radiological Health (CDRH) guidance for industry.
|
|
Radiation-Induced Immune Dysfunction Meeting
|
Meeting/ Workshop
|
ASPR
|
NIAID
|
The purpose of the workshop held in 2021 was to bring investigators together from the radiation biology and basic immunology fields to examine effects of radiation-induced hematopoietic injury, including natural history, early effects, recovery and residual damage. An RFA was issued on this topic, with eight awards made in 2022, and a meeting report has been accepted for publication in Radiation Research (anticipated early 2023).
|
|
Radiation-Induced Multi Organ Dysfunction Meeting Planning Group
|
Meeting/ Workshop
|
ASPR
|
NIAID, NCI
|
The objectives of the workshop are to 1) explore radiation-induced multi-organ injury, in particular, the connections and underlying mechanisms driving injury to affected organs; 2) assess how various treatments can ameliorate these injuries; and 3) publish a meeting report in a peer-review journal. Meeting will be held November 2-3, 2021.
|
|
Radiobiology Bioterrorism Research and Training Group (RABRAT)
|
Committee, Work group, Advisory group, or Task Force
|
FDA, ASPR
|
NCI, NIAID
|
This activity involves monthly meetings to discuss research initiatives, funding opportunities, training, conferences, publications, and other events and information related to preparing the US Government to respond to nuclear terrorism. Radiation review and conversation of subject matter experts across the USG.
|
|
Rapid Acceleration of Diagnostics Tech Program (RADx Tech)
|
Research Initiative
|
CMS, FDA, CDC, ASPR
|
NIBIB
|
To help address the COVID-19 pandemic, National Institute of Biomedical Imaging and Bioengineering (NIBIB) received $651 million (in FY2021) to support the development of new SARS-CoV-2 virus testing technologies. The Rapid Acceleration of Diagnostics (RADx®) Tech program is leveraging NIBIB's existing Point-of-Care Technologies Research Network (POCTRN) to accelerate the development, validation, and commercialization of innovative POC and home-based tests, as well as improvements to existing clinical laboratory methods. RADx Tech is supporting the full range of product development including technology validation, clinical translation, commercialization, and product distribution. RADx Tech also established the Independent Test Assessment Program (ITAP) in order to accelerate regulatory review and availability of high-quality, accurate, and reliable over-the-counter COVID-19 tests to the public.
|